Dr Angela Rezo

Dr Angela Rezo

MBBS (Hons), BSc (Med), FRANZCR
Radiation Oncologist
Become a Patient

With more than 20 years of experience in radiation oncology, Dr Angela Rezo is committed to delivering high-quality, personalised and evidence-based modern cancer treatment. She is an excellent communicator and strives to ensure her patients are well-informed of the treatment options available to them.


Dr Angela Rezo is an experienced radiation oncologist at Icon Cancer Centre Canberra. Born and raised in Canberra, Dr Rezo completed her Bachelor of Medicine, Bachelor of Surgery (MBBS) with Honours at the University of New South Wales in 1995. She subsequently undertook specialist radiation oncology training at Peter MacCallum Cancer Centre and The Canberra Hospital where she completed a fellowship at the Australian National University (ANU) Medical School. She became a fellow of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 2005.

Since returning to Canberra with her young family in 2004, Dr Rezo has been passionate about ensuring people in the Canberra region have timely access to modern radiation therapy. She is a clinical leader in implementing stereotactic brain and body radiation therapy in Canberra and has been a major contributor to the ACT & SENSW Breast Cancer Treatment Group. She maintains a strong interest in clinical trials, research and medical education. As well as supervising numerous research projects, she is part of the lung, breast and brain cancer multidisciplinary teams in Canberra and also a senior lecturer at the ANU Medical School, supervisor of specialists in-training and an investigator in clinical trials.

Her clinical experience covers a broad range of solid tumour malignancies with a special interest in breast cancer, lung cancer, brain cancer and spinal (CNS), and palliative care.

Affiliations & Memberships

  • ACT & SENSW Breast Cancer Treatment Group
  • Cooperative Trials Group for Neuro-Oncology (COGNO)
  • International Association for the Study of Lung Cancer (IASLC)
  • International Stereotactic Radiotherapy Society (ISRS)
  • Royal Australian and New Zealand College of Radiologists (RANZCR)
  • Trans-Tasman Radiation Oncology Group (TROG)

Special Interests

Dr Angela Rezo accepts referrals for all cancer types, with a special clinical interest in:
  • Brain and spinal (CNS) cancer
  • Breast cancer
  • Lung cancer
  • Palliative care

Icon Locations

Canberra View centre

Visiting Locations

  • The Canberra Hospital


  • Temporal impact of the publication of guidelines and randomised evidence on the adoption of hypofractionated whole breast radiotherapy for early-stage breast cancer. Jung KYK, Shadbolt B, Rezo A. Journal of Medical Imaging and Radiation Oncology, 2019 Aug; 63(4):530-537. 

  • Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Solomon B; TROG 09.02 CHISEL investigators. The Lancet Oncology. 2019 Apr;20 (4):494-503

  • IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer. Lakhanpal, I. Sestak, B. Shadbolt, G.M. Bennett, M. Brown, T. Phillips, Y. Zhang, A. Bullman & A. Rezo. Breast, 2016 Oct; 29:147-52.

  • Audiovisual biofeedback breathing guidance for lung cancer patients receiving radiotherapy: a multi-institutional phase II randomised clinical trial. Pollock, R. O’Brien, K. Makhija, F. Hegi-Johnson, J. Ludbrook, A. Rezo, R. Tse, T. Eade, R. Yeghiaian-Alvandi, V. Gebski & P.J. Keall. BMC Cancer, 2015; 18(15):526.

  • Numb chin syndrome: a case series of a clinical syndrome associated with malignancy. N. Tejani, A. Cooper, A. Rezo, Pranavan & D. Yip. Journal of Medical Imaging and Radiation Oncology, 2014; 58(6):700-5.

  • Surgical margins and risk of locoregional recurrence in invasive breast cancer: an analysis of 10-year data from the Breast Cancer Treatment Quality Assurance Project. E.C. Behm, K.R. Beckmann, J.E. Dahlstrom, Y. Zhang, C. Cho, R. Stuart-Harris, P. Craft, A. Rezo & J.M. Buckingham. Breast, 2013; 22(5): 839-44.

  • Tumor size and survival in multicentric and multifocal breast cancer. A. Rezo, J. Dahlstrom, B. Shadbolt, K. Rodins, Y. Zhang & A.J. Davis; ACT & SENSW BCTG. 2011; 20(3): 259-63.